FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileClarity Pharmaceuticals Ltd
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
CU6.AX
Clarity Pharmaceuticals Ltd Stock AnalysisComprehensive stock analysis for Clarity Pharmaceuticals Ltd (CU6.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCU6.AX
CU6.AX
Clarity Pharmaceuticals Ltd
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
CU6.AX
  1. Home
  2. Stocks
  3. Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

🇦🇺CU6.AX•ASX

Clarity Pharmaceuticals Ltd

🇦🇺CU6.AX•ASX

Your view on CU6.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Clarity Pharmaceuticals Ltd

Industry
Medical - Specialties
Sector
Healthcare
CEO
Michelle Parker
Headquarters
National Innovation Centre, Sydney, NSW, AU
Industry
Medical - Specialties
Sector
Healthcare
CEO
Michelle Parker
Headquarters
National Innovation Centre, Sydney, NSW, AU
Description

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer.

It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer.

The company was incorporated in 2010 and is based in Sydney, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Clarity Pharmaceuticals Ltd. Starting points for Clarity Pharmaceuticals Ltd: EPS -AUD 0.29, beta 1.18 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Clarity Pharmaceuticals Ltd. Clarity Pharmaceuticals Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Clarity Pharmaceuticals Ltd. Trailing twelve-month EPS for Clarity Pharmaceuticals Ltd stands at -AUD 0.29. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 21, 2026
More →

Earnings per share estimates

Per shareThis quarterMar 2023Next quarterDec 2024This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 0.00−AUD 0.07−AUD 0.31−AUD 0.30
Lowest estimateAUD 0.00−AUD 0.07−AUD 0.40−AUD 0.45
Highest estimateAUD 0.00−AUD 0.07−AUD 0.23−AUD 0.06
Number of analysts0155
A year ago——−AUD 0.291—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterMar 2023Next quarterDec 2024This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 6.55MAUD 5.92MAUD 16.00MAUD 32.97M
Lowest estimateAUD 6.55MAUD 5.92MAUD 3.03MAUD 6.25M
Highest estimateAUD 6.55MAUD 5.92MAUD 29.62MAUD 61.04M
Number of analysts2144
A year ago——AUD 0.00—
Growth vs a year ago————

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Clarity Pharmaceuticals Ltd. Clarity Pharmaceuticals Ltd has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CU6.AX15 companies · 8 funds
Compare CU6.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
CYC.AXCyclopharm LimitedHealthcareMedical - Devices—
RAD.AXRadiopharm Theranostics LimitedHealthcareBiotechnology—
TLX.AXTelix Pharmaceuticals LimitedHealthcareBiotechnology—
More Medical - Specialties companies
TickerTypeCompanySectorExchangeMkt cap
ANIKAnika Therapeutics, Inc.HealthcareNASDAQ$177.2M
APYXApyx Medical CorporationHealthcareNASDAQ$101.1M
ASFXAmerican Scientific Resources, IncorporatedHealthcareOTC$7,001
AVTIAvitar, Inc.HealthcareOTC$1,382
BEATHeartBeam, Inc.HealthcareNASDAQ$17.4M
BEATWHeartBeam, Inc.HealthcareNASDAQ$6.6M
BIELBioElectronics CorporationHealthcareOTC$7.2M
BMGPBiomagnetics Diagnostics Corp.HealthcareOTC$1,265
BRSYFBrainsWay Ltd.HealthcareOTC$451.7M
BTTXBetter Therapeutics, Inc.HealthcareOTC$5,452
BWAYBrainsWay Ltd.HealthcareNASDAQ$332.6M
CPYTCarePayment Technologies, Inc.HealthcareOTC$1,667
ETFs holding Clarity Pharmaceuticals Ltd
TickerFundFund assets% of the fund
VXUSVanguard Total International Stock ETF$163.2B in assets0.00%
VEAVanguard FTSE Developed Markets ETF$231.6B in assets0.00%
IEFAiShares Core MSCI EAFE ETF$188.8B in assets0.00%
VSSVanguard FTSE All-World ex-US Small-Cap ETF$11.6B in assets0.01%
GWXState Street SPDR S&P International Small Cap ETF$882M in assets0.03%
IPACiShares Core MSCI Pacific ETF$2.6B in assets0.00%
VIU.TOVanguard FTSE Developed All Cap ex North America Index ETF$11.4B in assets0.00%
VSGXVanguard ESG International Stock ETF$6.7B in assets0.00%

Largest holders first, then the funds most concentrated in CU6.AX.

Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Clarity Pharmaceuticals Ltd.

CU6.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1